Abstract
Severe asthma is associated with substantial productivity loss and activity impairment. In the real-world REALITI-A study, mepolizumab reduced clinically significant exacerbations and oral corticosteroid use in patients with severe asthma. Although mepolizumab improved activity impairment and work productivity in clinical trials, real-world data are limited. This post hoc analysis assessed the real-world impact of mepolizumab treatment on work productivity and daily activity impairment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
